Journal Article

DKFZ-2022-01878

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Including Measures of Chronic Kidney Disease to Improve Cardiovascular Risk Prediction by SCORE2 and SCORE2-OP.

Matsushita, K. ; Kaptoge, S. ; Hageman, S. H. ; Sang, Y. ; Ballew, S. H. ; Grams, M. E. ; Surapaneni, A. ; Sun, L. ; Arnlov, J. ; Bozic, M. ; Brenner, H.DKFZ* ; Brunskill, N. J. ; Chang, A. R. ; Chinnadurai, R. ; Cirillo, M. ; Correa, A. ; Ebert, N. ; Eckardt, K. U. ; Gansevoort, R. T. ; Gutierrez, O. ; Hadaegh, F. ; He, J. ; Hwang, S. J. ; Jafar, T. H. ; Jassal, S. K. ; Kayama, T. ; Kovesdy, C. P. ; Landman, G. W. ; Levey, A. S. ; Lloyd-Jones, D. M. ; Major, R. W. ; Miura, K. ; Muntner, P. ; Nadkarni, G. N. ; Nowak, C. ; Ohkubo, T. ; Pena, M. J. ; Polkinghorne, K. R. ; Sairenchi, T. ; Schaeffner, E. ; Schneider, M. P. ; Shalev, V. ; Shlipak, M. G. ; Solbu, M. D. ; Stempniewicz, N. ; Tollitt, J. ; Valdivielso, J. M. ; van der Leeuw, J. ; Wang, A. Y. M. ; Wen, C. P. ; Woodward, M. ; Yamagishi, K. ; Yatsuya, H. ; Zhang, L. ; Dorresteijn, J. A. ; Di Angelantonio, E. ; Visseren, F. L. ; Pennells, L. ; Coresh, J. ; Consortium, C. K. D. P. (Collaboration Author)

2023
Sage Publ. London [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1093/eurjpc/zwac176

Abstract: The 2021 ESC guideline on cardiovascular disease (CVD) prevention categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, SCORE2 and SCORE2-OP, to predict CVD risk. We developed and validated an 'Add-on' to incorporate CKD measures into these algorithms, using a validated approach.In 3,054,840 participants from 34 datasets, we developed three Add-ons (eGFR only, eGFR + urinary albumin-to-creatinine ratio [ACR] [the primary Add-on], and eGFR + dipstick proteinuria) for SCORE2 and SCORE2-OP. We validated c-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,997,719 participants from 34 different datasets.In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved c-statistic by 0.006 (95%CI 0.004-0.008) and 0.016 (0.010-0.023), respectively, for SCORE2 and 0.012 (0.009-0.015) and 0.024 (0.014-0.035), respectively, for SCORE2-OP. Similar results were seen when we included individuals with diabetes and tested the CKD Add-on (eGFR + dipstick). In 57,485 European participants with CKD, SCORE2 or SCORE2-OP with a CKD Add-on showed a significant NRI (e.g., 0.100 [0.062-0.138] for SCORE2) compared to the qualitative approach in the ESC guideline.Our Add-ons with CKD measures improved CVD risk prediction beyond SCORE2 and SCORE2-OP. This approach will help clinicians and patients with CKD refine risk prediction and further personalize preventive therapies for CVD.

Keyword(s): cardiovascular disease ; chronic kidney disease ; meta-analysis ; risk prediction

Note: 2023 Jan 11;30(1):8-16

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2022

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---